Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

SER-109 · Vowst

Microbiome therapy · Immune activation · developed by Aimmune Therapeutics

Approved FDA, Apr 2023
1 Registered trials

What is SER-109?

Vowst (fecal microbiota spores, live-brpk) is a purified suspension of encapsulated eubacterial spores enriched from healthy donor stool. It restores the microbiota ecology to treat Clostridium difficile infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vowst
Drug type
Microbiome therapy
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Aimmune Therapeutics, Inc.
In trials of
MCRB
FDA status
Approved as Vowst (April 26, 2023), BLA125757

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03183128 Phase 3 Clostridium Difficile Infection Completed MCRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clostridium Difficile Infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.